These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 21624991)

  • 1. Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.
    Young RJ; Gupta A; Shah AD; Graber JJ; Zhang Z; Shi W; Holodny AI; Omuro AM
    Neurology; 2011 May; 76(22):1918-24. PubMed ID: 21624991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients.
    Bani-Sadr A; Berner LP; Barritault M; Chamard L; Bidet CM; Eker OF; Hermier M; Guyotat J; Jouanneau E; Meyronet D; Gouttard S; D'Hombres A; Iziquierdo C; Honnorat J; Berthezène Y; Ducray F
    Rev Neurol (Paris); 2019 Oct; 175(9):534-543. PubMed ID: 31208813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
    Xi J; Hassan B; Katumba RGN; Khaddour K; Govindan A; Luo J; Huang J; Campian JL
    BMC Cancer; 2021 Mar; 21(1):285. PubMed ID: 33726710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas.
    de Godoy LL; Mohan S; Wang S; Nasrallah MP; Sakai Y; O'Rourke DM; Bagley S; Desai A; Loevner LA; Poptani H; Chawla S
    J Transl Med; 2023 Apr; 21(1):287. PubMed ID: 37118754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
    Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
    J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.
    Galldiks N; Dunkl V; Stoffels G; Hutterer M; Rapp M; Sabel M; Reifenberger G; Kebir S; Dorn F; Blau T; Herrlinger U; Hau P; Ruge MI; Kocher M; Goldbrunner R; Fink GR; Drzezga A; Schmidt M; Langen KJ
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):685-95. PubMed ID: 25411133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
    Pinho MC; Polaskova P; Kalpathy-Cramer J; Jennings D; Emblem KE; Jain RK; Rosen BR; Wen PY; Sorensen AG; Batchelor TT; Gerstner ER
    Oncologist; 2014 Jan; 19(1):75-81. PubMed ID: 24309981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.
    Kebir S; Fimmers R; Galldiks N; Schäfer N; Mack F; Schaub C; Stuplich M; Niessen M; Tzaridis T; Simon M; Stoffels G; Langen KJ; Scheffler B; Glas M; Herrlinger U
    Clin Cancer Res; 2016 May; 22(9):2190-6. PubMed ID: 26673798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.
    Rowe LS; Butman JA; Mackey M; Shih JH; Cooley-Zgela T; Ning H; Gilbert MR; Smart DK; Camphausen K; Krauze AV
    J Neurooncol; 2018 Aug; 139(1):145-152. PubMed ID: 29767308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
    Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
    Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value.
    Yoo RE; Choi SH; Kim TM; Lee SH; Park CK; Park SH; Kim IH; Yun TJ; Kim JH; Sohn CH
    AJNR Am J Neuroradiol; 2015 Oct; 36(10):1846-52. PubMed ID: 26294653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma.
    Verma G; Chawla S; Mohan S; Wang S; Nasrallah M; Sheriff S; Desai A; Brem S; O'Rourke DM; Wolf RL; Maudsley AA; Poptani H
    NMR Biomed; 2019 Feb; 32(2):e4042. PubMed ID: 30556932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
    Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
    BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
    Boxerman JL; Ellingson BM; Jeyapalan S; Elinzano H; Harris RJ; Rogg JM; Pope WB; Safran H
    Am J Clin Oncol; 2017 Jun; 40(3):228-234. PubMed ID: 25436828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas.
    Baek HJ; Kim HS; Kim N; Choi YJ; Kim YJ
    Radiology; 2012 Sep; 264(3):834-43. PubMed ID: 22771885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A deep learning model for discriminating true progression from pseudoprogression in glioblastoma patients.
    Moassefi M; Faghani S; Conte GM; Kowalchuk RO; Vahdati S; Crompton DJ; Perez-Vega C; Cabreja RAD; Vora SA; Quiñones-Hinojosa A; Parney IF; Trifiletti DM; Erickson BJ
    J Neurooncol; 2022 Sep; 159(2):447-455. PubMed ID: 35852738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence.
    Radbruch A; Fladt J; Kickingereder P; Wiestler B; Nowosielski M; Bäumer P; Schlemmer HP; Wick A; Heiland S; Wick W; Bendszus M
    Neuro Oncol; 2015 Jan; 17(1):151-9. PubMed ID: 25038253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
    Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.
    Dworkin M; Mehan W; Niemierko A; Kamran SC; Lamba N; Dietrich J; Martinez-Lage M; Oh KS; Batchelor TT; Wen PY; Loeffler JS; Shih HA
    J Neurooncol; 2019 Mar; 142(1):69-77. PubMed ID: 30488294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
    Moon HH; Kim HS; Park JE; Kim YH; Kim JH
    BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.